Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

Delayed Quote. Delayed  - 06/24 05:32:00 pm
75.75 CHF   -1.56%
06/23 NOVARTIS : Field Service Workers Represented by Nichols Kaster, PLLP..
06/22 Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
06/22 NOVARTIS : Timely use of Novartis' Entresto could prevent or postpon..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

UK's NICE Backs Novartis Eye Drug, Reversing Earlier Guidance

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/05/2012 | 01:16am CEST

By Marta Falconi

ZURICH--The U.K.'s health costs watchdog has reversed earlier guidance and now recommends eye drug Lucentis for a new use, after its maker Novartis AG (>> Novartis AG) offered a better price.

The U.K's National Institute for Health and Clinical Excellence, or NICE, recommends the drug for certain patients who suffer from visual impairment caused by diabetic macular oedema, the regulator said Friday. Without discount, Lucentis costs 742.17 pounds ($1,195) per injection and is given monthly, NICE said.

The new draft guidance is now up for consultation.

NICE decides if particular treatments should be used on the state-run National Health Service. The watchdog had previously rejected Lucentis for diabetic macular oedema, a condition caused by fluid collecting in the central part of the retina, which leads to blurred central vision and other problems.

The drug is already recommended to treat wet age-related macular degeneration.

Novartis said it was pleased with NICE's decision, but lamented the watchdog's move to restrict Lucentis to only those patients with more thickened retinas.

"This has undervalued the benefits that Lucentis provides to all patients with visual impairment due to diabetic macular oedema," the company said.

The Swiss company said it will continue to work with NICE and other health authorities until final draft guidance is issued by early 2013.

Lucentis, which generated nearly 2.05 billion Swiss francs ($2.19 billion) in sales in 2011, was co-developed by Novartis and Swiss rival Roche Holding AG (ROG.VX). Novartis markets the medicine outside the U.S.

Write to Marta Falconi at marta.falconi@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Novartis AG
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on NOVARTIS AG
06/23 NOVARTIS : Sandoz Canada Concludes a New Collective Agreement With Unionized Emp..
06/23 NOVARTIS : Patent Issued for Sharp Fixation Target (USPTO 9364141)
06/23 NOVARTIS : Field Service Workers Represented by Nichols Kaster, PLLP and JTB Law..
06/22 Roche CEO 'sleeps better' as risk to drugmaker's growth recedes
06/22 NOVARTIS : Timely use of Novartis' Entresto could prevent or postpone over 28,00..
06/22 NOVARTIS : Next-generation antimalarial treatment
06/21 NOVARTIS : "Pure Nebraska" segments filmed at Sandoz Center
06/21 NOVARTIS : CSC professor cycling to Kearney for Sandoz meeting
06/20 Novartis aims to triple biosimilar drugs by 2020
06/20 NOVARTIS : Reigniting the malaria fight
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials